 |
Meetings by European Networks | Satellite
Symposia | Official Opening & José Carreras
Lecture
MEETING OF THE EHA WORKSHOP ON MDS IN ASSOCIATION
WITH THE MDS WORKING GROUP OF THE EUROPEAN LEUKEMIANET
08:00 – 10:00, Room Le Cervin (Geneva Palexpo)
| Chairs: |
P. Fenaux (Hospital Avicenne, Paris, France)
T. de Witte (University Medical Centre St. Radboud, Nijmegen,
The Netherlands) |
 |
MANAGEMENT STRUCTURE OF MDS WP |
| |
PROPOSAL OF DEFINITIONS AND STANDARDIZATION OF
|
| |
PROPOSAL OF DEFINITIONS AND STANDARDIZATION OF
RELEVANT DIAGNOSTIC AND THERAPEUTIC PROCEDURES |
| |
STANDARD EUROPEAN NETWORK PROTOCOLS; LIST OF
ALL
PROTOCOLS OF TRIALS BY MDS STUDY GROUPS IN EUROPE |
| |
IMPLEMENTATION AND COORDINATION OF ONGOING AND
NEW
CLINICAL TRIALS |
| |
MINUTES OF KICK-OFF MEETING HEIDELBERG 27-28
JANUARY
2004-05-07 |
SECOND MEETING OF THE EHA WORKING GROUP
ON THROMBOCYTOPENIAS
08.00 – 10.00, Room H (Geneva Palexpo)
| |
INTRODUCTION AND SUMMARY OF
ONGOING ACTIVITIES
F. Rodeghiero (Vicenza, Italy) and D. Provan (London, United
Kingdom) |
| |
DRUG-INDUCED THROMBOCYTOPENIA
J.N. George (Oklahoma, USA) |
| |
INHERITED THROMBOCYTOPENIAS: A PROPOSED
DIAGNOSTIC ALGORITHM FROM THE ITALIAN GSP (STUDY GROUP ON PLATELETS)
C. Balduini (Pavia, Italy) |
| |
ICIS-PARC STUDY UPDATE
P. Imbach (Basel, Switzerland) |
| |
HIGH DOSE DEXAMETHASONE IN PREVIOUSLY
UNTREATED ITP PATIENTS: RESULTS FROM A PILOT STUDY OF GIMEMA
ITP GROUP
M.G. Mazzucconi (Rome, Italy) |
| |
PROPOSALS AND BRIEF COMMUNICATIONS
Members of the WG at large |
|
CONCLUSIONS AND FUTURE PERSPECTIVES
F. Rodeghiero (Vicenza, Italy) |
|
|
ESPHI ASSEMBLY
08:00 – 10:00, Room I (Geneva Palexpo)
| Chairs: |
L. Márodi (Hungary)
S. v. Mackensen (Germany) |
EMN ANNUAL MEETING
08:00 – 10:00, Room E (Geneva Palexpo)
| |
THERAPY OF REFRACTORY AND
RELAPSED DISEASE AND A PROPOSAL FOR A REVILIMID TRIAL?
P. Sonneveld |
| |
PRESENT SITUATION ON THALIDOMIDE PROTOCOLS
AND A PLAN FOR META ANALYSIS?
A. Waage |
| |
TOWARDS STANDARDIZATION OF FISH AND FLOW
CYTOMETRY IN MM?
H. Avetloiseau and H.E. Johnsen |
| |
EMN ANNUAL BUSINESS MEETING 2004
P. Sonneveld (EMN Chairman) |
MEETING ORGANIZED BY THE EUROPEAN LEUKEMIANET
08:00 – 10:00, Salon 2 (Villa Sarasin, Ground floor)
| Chairs: |
M.A. Sanz (Hospital Universitario La Fe, Valencia,
Spain) |
MEETING ORGANIZED BY THE EUROPEAN LEUKEMIANET
08:00 – 10:00, Salon 3 (Villa Sarasin, Ground floor)
| Chairs: |
T. de Witte (University Medical Centre St. Radboud,
Nijmegen, The Netherlands) |
MEETING ORGANIZED
BY THE EUROPEAN LEUKEMIANET
08:00 – 10:00, Salon 11 (Villa Sarasin, 1st floor)
| Chairs: |
E. Gluckman (Hôpital Saint Louis, Paris,
France) |
MEETING ORGANIZED BY THE EUROPEAN LEUKEMIANET
08:00 – 10:00, Salon 17 (Villa Sarasin, 1st floor)
| Chairs: |
D. Niederwieser (University of Leipzig, Leipzig,
Germany) |
|
SATELLITE SYMPOSIUM
SUPPORTED BY NOVARTIS ONCOLOGY
10:30 – 12:30, Room C (Geneva Palexpo)
| Chairs: |
H. Kantarjian (Leukemia Department, MD Anderson
Cancer Center, Houston, USA) |
| |
10:30 – 10:35 |
| |
INTRODUCTION
H. Kantarjian |
| |
10:35 – 10:50 |
| |
IMATINIB IN CML – THE STATE OF THE
ART
J.N. George (Oklahoma, USA) |
| |
10:50 – 11:05 |
| |
NOVEL STRATEGIES IN CML, INCLUDING HIGH-DOSE
IMATINIB AND COMBINATIONS
H. Kantarjian |
| |
11:05 – 11:20 |
| |
MONITORING RESIDUAL DISEASE AND RESISTANCE
ON IMATINIB THERAPY
T. Hughes (Royal Adelaide Hospital, Institute of Medical &
Veterinary Science, Division of Hematology, Adelaide, Australia) |
| |
11:20 – 11:35 |
| |
TREATMENT DECISIONS IN THE IMATINIB ERA:
BMT VS. IMATINIB
J.M. Goldman (Imperial College London, Dept. of Hematology,
Hammersmith Hospital, London, United Kingdom) |
| |
11:35 – 11:45 |
|
IMATINIB IN PH+ ALL
D. Thomas (Leukemia Department M.D. Anderson Cancer Center Houston,
USA) |
| |
11:45 – 11:55 |
|
IMATINIB IN HEMATOLOGIC DISORDERS OTHER
THAN CML
R. Stone (Dana Farber Cancer Institute, Dana, Boston, USA) |
| |
11:55 – 12:25 |
|
DISCUSSION
Lead by H. Kantarjian |
| |
12:25 – 12:30 |
|
CLOSING REMARKS
H. Kantarjian |
|
|
This symposium has been accredited under the EHA-ECAH pilot
project and attending physicians are entitled to receive 2 CME
credit points on completion of the evaluation form. See page
10 for details.
Commercial affiliations
S.G. O’Brien, Research support, Consultant, Speakers’
Bureau
H. Kantarjian, Research support
T. Hughes, Research support, Speakers’ Bureau, Scientific
Advisory Board
J.M. Goldman, Speakers’ Bureau, Scientific Advisory
Board
D. Thomas, Research support, Scientific Advisory Board
R. Stone, Speakers’ Bureau, Scientific Advisory Board |
SATELLITE SYMPOSIUM SUPPORTED BY ABBOTT
10:30 – 12:30, Room La Saleve (Geneva Palexpo)
| Chairs: |
A.R. Green (United Kingdom) |
| |
DOUBLE JEOPARDY FROM A SINGLE
TRANSLOCATION - THE ROLE OF FISH IN CHRONIC MYELOID LEUKEMIA
A.R. Green (United Kingdom) |
| |
SIGNIFICANCE OF PROGNOSTIC FACTORS IN
CLL AND IMPLICATIONS FOR PATIENT MANAGEMENT
L. Bergmann (Germany) |
| |
FISH DETECTION OF CYTOGENETIC ABNORMALITIES
IN CLL
S. Raynaud (France) |
| |
DNA FISH PROBES FOR HEMATOLOGICAL CANCER:
NEW DEVELOPMENTS
J. Proffitt (USA) |
This symposium has been accredited under the EHA-ECAH pilot
project
and attending physicians are entitled to receive 2 CME credit
points on
completion of the evaluation form. See page 10 for details.
Commercial affiliations
A.R. Green, Speakers Bureau
L. Bergmann, No Affiliations
S.D. Raynaud, Speakers’ Bureau
J.H. Profitt, Employee |
|
Top
SATELLITE SYMPOSIUM SUPPORTED BY CELGENE
10:30 – 12:30, Room D
| |
10:00-10:30 |
| |
REGISTRATION |
| |
10:30-10:35 |
| |
Welcome AND INTRODUCTION
Fenaux (French MDS Group, Hôpital Avicenne/Paris 13, Bobigny,
France) |
| |
10:35-10:55 |
| |
IMiDs™: A NOVEL CLASS OF IMMUNOMODULATORS
R.D. Knight (VP Clinical R&D Oncology, Celgene Corporation,
Warren,
New Jersey, USA) |
| |
10:55-11:20 |
| |
A COMPARATIVE REVIEW OF CLASSIFICATION
SYSTEMS IN MDS
J.M. Bennett (James P. Wilmot Cancer Center University of Rochester,
Medical Center Rochester, Rochester, New York, USA) |
| |
11:20-11:45 |
| |
TREATMENT STRATEGIES AND ISSUES IN LOW
TO INTERMEDIATE-1 RISK PATIENTS
D.T. Bowen (MRCPath, Division of Pathology and Neurosciences,
University of Dundee, Dundee, Scotland, UK) |
| |
11:45- 12:10 |
|
EMERGING DATA WITH IMiDs™ IN THE
TREATMENT OF MDS
A.F. List, (Malignant Hematology, Program Leader H. Lee Moffitt
Cancer
Center & Research Institute, Tampa, Florida, USA) |
| |
12:10-12:25 |
|
PANEL DISCUSSION
Faculty |
| |
12:25 - 12:30 |
|
CLOSING REMARKS
P. Fenaux |
| |
12:25 – 12:30 |
|
CLOSING REMARKS
H. Kantarjian |
SATELLITE SYMPOSIUM SUPPORTED BY LIPOMED AG
10:30 – 12:30, Room H (Geneva Palexpo)
| Chairs: |
D. Linch (University College London, Department
of Hematology, London, United Kingdom)
D. Hoelzer (Johan Wolfgang Goethe University, Frankfurt, Germany)
|
| |
10:30 - 10:40 |
| |
INTRODUCTION
D. Hoelzer (Johan Wolfgang Goethe University, Frankfurt, Germany)
|
|
|
| |
10:40 – 10:50 |
| |
ROUTES AND SCHEDULING OF CLADRIBINE
ADMINISTRATION BASED ON PHARMACOKINETICS
G. Juliusson (Lund University, Department of Hematology, University
Hospital, Lund, Sweden) |
| |
10:50 – 11:05 |
| |
EXPERIENCE WITH SUBCUTANEOUS CLADRIBINE
IN INDOLENT LYMPHOMAS
U. Hess (Kantonspital St. Gallen, Fachbereich Onkologie Hematologie,
St. Gallen, Switzerland) |
| |
11:05 – 11:20 |
| |
TREATMENT OF HAIRY CELL LEUKEMIA WITH
CLADRIBINE
M. Rummel (Germany) |
| |
11:20 – 11:35 |
| |
TREATMENT OF WALDENSTROM’S MACROGLOBULINAEMIA
WITH CLADRIBINE AND CLADRIBINE BASED COMBINATIONS
M.A. Dimopoulos (University of Athens, Department of Athens
School
of Medicine, Athens, Greece) |
| |
11:35 – 11:50 |
| |
CLINICAL EXPERIENCE WITH PURINE ANALOGUES
IN CHRONIC LYMPHOCYTIC LEUKEMIA
G. Juliusson (Lund University, Department of Hematology, University
Hospital, Lund, Sweden) |
| |
11:50 – 12:05 |
|
COMBINATION TREATMENT REGIMENS WITH CLADRIBINE
IN INDOLENT LYMPHOMAS
S. Rule (Derriford Hospital, Plymouth, United Kingdom) |
| |
12:05 – 12:15 |
|
CONCLUSION
D. Linch (University College London, Department of Hematology,
London, United Kingdom) |
| |
12:15 – 12:30 |
|
DISCUSSION |
This symposium has been accredited under the EHA-ECAH pilot
project
and attending physicians are entitled to receive 2 CME credit
points on
completion of the evaluation form. See page 10 for details.
Commercial affiliations
D. Hoelzer, No Affiliations
U. Hess, No Affiliations
M. Rummel, No Affiliations
M.A. Dimopoulos, No Affiliations
G. Juliusson, No Affiliations
S. Rule, No Affiliations
D. Linch, Consultant |
|
Top
SATELLITE SYMPOSIUM SUPPORTED BY SCHERING AG
13:15 – 15:15, Room A/B (Geneva Palexpo)
| Chair: |
J. Radford (Department of Medical Oncology, Christie
Hospital, Manchester, United Kingdom) |
| |
13:20 – 13:40 |
| |
CURRENT THERAPEUTIC APPROACHES
TO NHL
F. D’Amore (Department of Haematology, Aarhus University
Hospital,
Denmark) |
| |
13:40 – 14:00 |
| |
RADIOIMMUNOTHERAPY: THE EMERGING ROLE
OF ZEVALIN® IN THE TREATMENT OF NHL
F. Morschhauser (Claude Huriez Hospital, CHU Lille, Lille, France) |
| |
14:00 – 14:20 |
| |
PRACTICAL ASPECTS OF ZEVALIN® RADIOIMMUNOTHERAPY
V. Lewington (Royal Marsden Hospital, Sutton, United Kingdom) |
| |
14:20 – 14:40 |
| |
OPTIMIZING TREATMENT OF CLL WITH FLUDARA®
J-F. Rossi (Department of Haematology and Medical Oncology,
University Hospital Montpellier, France) |
| |
14:40 – 15:00 |
| |
ERADICATION OF MINIMAL RESIDUAL DISEASE
IN CLL: THE IMPORTANT ROLE OF MABCAMPATH®
P. Hillmen (Department of Haematology, Pinderfields General
Hospital, Wakefield, United Kingdom) |
| |
15:00 – 15:15 |
|
OVERVIEW AND CLOSE
J. Radford (Department of Medical Oncology, Christie Hospital,
Manchester, United Kingdom) |
SATELLITE SYMPOSIUM SUPPORTED BY ORTHO BIOTECH
13:15 – 18:00, Room C (Geneva Palexpo)
13:15 – 15:20 Part 1
15:20 – 16:00 Reception to meet the Bortezomib experts
16:00 – 18:00 Part 2
13:15 – 15:20 |
|
13:15 - 15:20
Co-Chairs: J.F. San Miguel, M. Boccadoro
| |
13:15 – 13:25 |
| |
A NEW ERA IN THE TREATMENT
OF MULTIPLE MYELOMA
M. Boccadoro |
| |
13:25 – 13:40 |
| |
PROTEASOME INHIBITION: A RATIONAL APPROACH
TO MULTIPLE MYELOMA
R. Orlowski |
| |
13:40 – 14:00 |
| |
BORTEZOMIB CLINICAL DEVELOPMENT
J.F. San Miguel |
| |
14:00 – 14:25 |
| |
PRACTICAL APPLICATION OF BORTEZOMIB THERAPY
IN MULTIPLE MYELOMA
P. Sonneveld |
| |
14:25 – 14:40 |
| |
EVOLVING COMBINATION TREATMENT OPTIONS
WITH BORTEZOMIB
J. Cavenagh |
| |
14:40 – 14:55 |
|
NEXT STEPS FOR BORTEZOMIB IN MULTIPLE
MYELOMA
S. Jagannath |
| |
14:55 – 15:15 |
|
PANEL DISCUSSION (BASED AROUND CASE STUDIES)
co-chairs et al. |
| |
15:15 – 15:20 |
|
CLOSING REMARKS
J.F. San Miguel |
This symposium (Part 1) has been accredited under the EHA-ECAH
pilot
project and attending physicians are entitled to receive 2 CME
credit points
on completion of the evaluation form. See page 10 for details.
Commercial affiliations
M. Boccadoro, Scientific Advisory Board
R. Orlowski, No affiliations
P. Sonneveld, No affiliations
J. Cavenagh, Speakers’ Bureau, Scientific Advisory
Board
S. Jagannath, No affiliations
J.F. San Miguel, Scientific Advisory Board |
15:20 – 16:00
|
Top
SATELLITE SYMPOSIUM SUPPORTED BY ORTHO BIOTECH
16:00 – 18:00, Room C (Geneva Palexpo)
| Co-Chairs: |
P. Gascón, H. Ludwig |
| |
16:00 – 16:05 |
| |
IMPROVEMENTS IN QUALITY OF
LIFE – NOW MORE IMPORTANT THEN EVER!
P. Gascón |
| |
16:05 – 16:25 |
| |
A DECADE OF EPOETIN ALFA IN CANCER ANEMIA
MANAGEMENT – DEVELOPMENT FOR PATIENT BENEFIT
H. Ludwig |
| |
16:25 – 16:40 |
| |
ANEMIA IN HEMATOLOGIC MALIGNANCIES –
HOW CAN IT BE PREDICTED?
P. Gascón |
| |
16:40 – 17:00 |
| |
OPTIMAL ANEMIA MANAGEMENT WITH EPOETIN
ALFA IN HM – FIRST RESULTS FROM THE MULTICENTER, EUROPEAN
EPOLYM TRIAL
H. Tesch |
| |
17:00 – 17:15 |
| |
QUALITY OF LIFE IN CANCER PATIENTS: CURRENT
AND FUTURE NEEDS
A. Palumbo |
| |
17:15 – 17:35 |
|
FARNESYL TRANSFERASE INHIBITORS –
NEXT PHASE IN RATIONAL DRUG DESIGN FOR THERAPEUTICS
P. Fenaux |
| |
17:35 – 17:50 |
|
PANEL DISCUSSION: STRATEGIES FOR PATIENT
TREATMENT AND CARE NOW AND IN THE FUTURE
co-chairs et al. |
| |
17:50 – 18:00 |
|
CLOSING REMARKS
H. Ludwig |
This symposium (Part 2) has been accredited under the EHA-ECAH
pilot project and attending physicians are entitled to receive
2 CME credit points on completion of the evaluation form. See
page 10 for details.
Commercial affiliations
P. Gascon, Speakers’ bureau H. Ludwig, Speakers’
bureau
H. Tesch, Research Support A. Palumbo, No affiliations
P. Fenaux, No affiliations |
|
|
SATELLITE SYMPOSIUM
SUPPORTED BY ROCHE
13:15 – 15:15, Room Mont Blanc (Geneva Palexpo)
| Chair: |
H Ludwig (Wilhelminenspital der Stadt Wien, Vienna,
Austria) |
| |
13:15 – 13:30 |
| |
INTRODUCTION – WHY MUST
WE TREAT ANEMIA IN PATIENTS WITH CANCER?
H. Ludwig (Wilhelminenspital der Stadt Wien, Vienna, Austria) |
| |
13:30 – 13:55 |
| |
WHAT ARE THE PROVEN BENEFITS OF EPOETINS
IN LYMPHOID MALIGNANCIES?
A. Österborg (Karolinska Institute & Hospital, Stockholm,
Sweden) |
| |
13:55 – 14:15 |
| |
OPTIMISING PATIENT AND PROVIDERS’
CONVENIENCE
B. Coiffier (Center Hospitalier Lyon-Sud, Pierre-Benite, France)
|
| |
14:15 – 14:50 |
| |
ANEMIA TREATMENT IN THE CONTEXT OF CANCER
PATIENT MANAGEMENT?
Case studies presented by:
R. García-Sanz (Hospital Universitario de Salamanca,
Salamanca, Spain)
H. Ludwig (Wilhelminenspital der Stadt Wien, Vienna, Austria)
A. Österborg (Karolinska Institute & Hospital, Stockholm,
Sweden) |
| |
14:50 – 14:55 |
| |
CHAIRMAN’S SUMMARY
H. Ludwig (Wilhelminenspital der Stadt Wien, Vienna, Austria) |
| |
14:55 – 15:10 |
|
OUTLOOK TO THE FUTURE OF ANEMIA MANAGEMENT
J. Spivak (John Hopkins, Department of Medicine, Baltimore,
USA) |
| |
15:10 – 15:15 |
|
QUESTIONS & ANSWERS |
|
Top
SATELLITE SYMPOSIUM
SUPPORTED BY PFIZER
13:15 – 15:15, Room D (Geneva Palexpo)
| |
13:15 – 13:20 |
| |
WELCOME AND OPENING REMARKS
C. Viscoli (Italy) |
| |
13:20 – 13:45 |
| |
EPIDEMIOLOGY OF FUNGAL INFECTIONS –
A SWISS PERSPECTIVE
T. Calandra (Switzerland) |
| |
13:45 – 14:10 |
| |
ANTIFUNGAL PROPHYLAXIS IN SEVERELY NEUTROPENIC
PATIENTS
M. Boogaerts (Belgium) |
| |
14:10 – 14:35 |
| |
IMPROVING OUTCOMES IN INVASIVE ASPERGILLOSIS
W. Steinbach (USA) |
| |
14:35 – 15:00 |
| |
NEW OPTIONS FOR CANDIDA BLOODSTREAM INFECTIONS
C. Viscoli (Italy) |
| |
15:00 – 15:10 |
|
PANEL DISCUSSION |
| |
15:10 – 15:15 |
|
CONCLUDING REMARKS
T. Calandra (Switzerland) |
| |
15:15 – 15:30 |
|
END |
|
|
SATELLITE SYMPOSIUM
SUPPORTED BY ROCHE
16:00 – 18:00 hours, Room A/B (Geneva Palexpo)
| |
16:00 – 16:10 |
| |
INTRODUCTION
F. Cavalli (Oncology Institute of Southern Switzerland, Switzerland) |
| |
16:10 – 16:30 |
| |
IMMUNOCHEMOTHERAPY – A NEW STANDARD
FIRST-LINE TREATMENT FOR FOLLICULAR NHL
R. Marcus (Addenbrookes Hospital, United Kingdom) |
| |
16:30 – 16:50 |
| |
MABTHERA® PLUS CHEMOTHERAPY IMPROVES
CLINICAL OUTCOMES IN INDOLENT NHL
W. Hiddemann (University Hospital Munich-Großhadern, Germany) |
| |
16:50 – 17:10 |
| |
PROLONGING REMISSION IN INDOLENT NHL:
THE ROLE OF MAINTENANCE THERAPY
S. Horning (Stanford University Medical Centre, USA) |
| |
17:10 – 17:30 |
| |
IMPROVING SURVIVAL IN YOUNGER PATIENTS
WITH AGGRESSIVE NHL
M. Pfreundschuh (University of Saarland, Germany) |
| |
17:30 – 17:50 |
|
THE SUPERIORITY OF R-CHOP IN AGGRESSIVE
NHL: FROM CLINICAL TRIALS TO COMMUNITY PRACTICE
L. Sehn (British Columbia Cancer Agency, Canada) |
| |
17:50 – 18:00 |
|
SUMMARY AND CLOSE
F. Cavalli (Oncology Institute of Southern Switzerland, Switzerland)
|
SATELLITE SYMPOSIUM SUPPORTED BY ORTHO BIOTECH
16:00 – 18:00, Room C (Geneva Palexpo)
For program details see page 29 and 30. |
Top
SATELLITE SYMPOSIUM SUPPORTED BY NOVARTIS ONCOLOGY
16:00 – 18:00, Room D (Geneva Palexpo)
| Chair: |
Ch. Hershko (Shaare Zedek Medical Center, Dept.
of Hematology,
Jerusalem, Israel) |
| |
16:00 – 16:10 |
| |
TREATING IRON OVERLOAD: THE
STATE OF THE ART
Ch. Hershko (Shaare Zedek Medical Center, Dept. of Hematology,
Jerusalem, Israel) |
| |
16:10 – 16:35 |
| |
IRON OVERLOAD IN THALASSEMIA AND SICKLE
CELL DISEASE
Ali Taher, (Hematology & Oncology, American University of
Beirut, Beirut, Lebanon) |
| |
16:35 – 17:00 |
| |
MANAGEMENT OF ANEMIA IN THE MYELODYSPLASTIC
SYNDROME (MDS)
E. Hellström-Lindberg (Department of Medicine at Huddinge
Hospital, Division of Hematology, Huddinge Universitetssjukhus,
Huddinge,
Sweden) |
| |
17:00 – 17:25 |
| |
TREATMENT AND MONITORING OF IRON OVERLOAD:
STATE OF THE ART AND NEW APPROACHES
J. Porter (University College London, Department of Hematology,
London, United Kingdom) |
| |
17:25 – 17:50 |
| |
THE IMPORTANCE OF COMPLIANCE IN IRON
CHELATION
M.D. Cappellini (Centro Anemie Congenite, Pad. Granelli Ospedale
Maggiore Policlinico, Milano, Italy) |
| |
17:50 – 18:00 |
|
DISCUSSION AND CONCLUSIONS
Ch. Hershko (Shaare Zedek Medical Center, Dept. of Hematology,
Jerusalem, Israel) |
This symposium has been accredited under the EHA-ECAH pilot
project
and attending physicians are entitled to receive 2 CME credit
points on
completion of the evaluation form. See page 10 for details.
Commercial affiliations
Ch. Hershko, Drug safety, Committee
A. Taher, Scientific Advisory Board
E. Hellström-Lindberg, No affiliation
J. Porter, Consultant, Scientific Advisory Board
M.D. Cappelini, Scientific Advisory Board |
|
|
SATELLITE SYMPOSIUM
SUPPORTED BY PHARMION LTD
16.00 - 18.00, Room La Salève (Geneva Palexpo)
| Chair: |
J-L. Harousseau (Hôpital Hotel Dieu, Nantes,
France) |
| |
16:00 – 16:10 |
| |
CHAIRMAN’S INTRODUCTION
J-L.Harousseau (Hôpital Hotel Dieu, Nantes, France) |
| |
16:10 – 16:30 |
| |
THALIDOMIDE AS A PHARMACEUTICAL PRODUCT
J. Backstrom (VP Global Medical and Safety, Pharmion Corporation,
Kansas City, USA) |
| |
16:30 – 16:55 |
| |
BIOLOGY OF MULTIPLE MYELOMA
G. Morgan (The Royal Marsden NHS Trust, Surrey, United Kingdom) |
| |
16:55 – 17:20 |
| |
TREATMENT OF RELAPSING AND RESISTANT
DISEASE
J.F. San Miguel (Hospital Clinico Universitario, Salamanca,
Spain) |
| |
17:20 – 17:50 |
| |
USE OF THALIDOMIDE AS A FIRST LINE AGENT
M. Boccadoro (Divisione Universitaria di Ematologia, Turin,
Italy) |
| |
17:50 – 18:00 |
|
DISCUSSION AND CLOSING REMARKS |
|
18:30 – 19:30, Plenary room (A+B+C, Geneva Palexpo)
| Chair: |
E. Montserrat (Hospital Clinic Barcelona, Barcelona,
Spain)
A. Gratwohl (Kantonsspital Basel, Basel, Switzerland) |
| |
18:30 – 19:00 |
| |
OPENING ADDRESS
A. Gratwohl (Kantonsspital Basel, Basel, Switzerland)
The State Council P.F. Unger (Geneva, Switzerland)
E. Montserrat (Hospital Clinic Barcelona, Barcelona, Spain) |
| |
19:00 – 19:30 |
| |
JOSÉ CARRERAS LECTURE
INTRODUCTION
E. Montserrat (Hospital Clinic Barcelona, Barcelona, Spain)
FROM THE ADSORBENT GLANDS TO THE
CURE OF PATIENTS WITH HODGKIN’S LYMPHOMAS
V. Diehl (Köln University, Köln, Germany)
|
| |
PRESENTATION JOSÉ CARRERAS – EHA
YOUNG INVESTIGATOR FELLOWSHIP GRANT FUND |
Top |
|
EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room A (Geneva Palexpo)
| Chair: |
B. Lämmle (Central Haematology Laboratory,
Bern, Switzerland) |
| |
THE ANTIPHOSPHOLIPID SYNDROME
J. Arnout (Medical University Leuven, Leuven, Belgium) |
| |
THROMBOTIC THROMBOCYTOPENIC PURPURA
B. Lämmle (Central Haematology Laboratory, Bern, Switzerland)
|
| |
IDIOPATHIC THROMBOCYTOPENIC PURPURA IN
ADULTS: CURRENT ISSUES FOR PATHOGENESIS, DIAGNOSIS AND MANAGEMENT
J.N. George (University of Oklahoma Health Sciences Center,
Oklahoma City, USA) |
EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room B (Geneva Palexpo)
| Chair: |
M.W. Huisman (Leiden University Medical Centre,
Leiden, The
Netherlands) |
| |
RELATIONS BETWEEN HEMOSTATIC
VARIABLES, INSULIN RESISTANCE AND INFLAMMATION
P. Morange (CHU Tirone, Marseille, France) |
| |
THROMBOSIS AND CANCER
A.K. Kakkar (Thrombosis Research Institute, London, United Kingdom)
|
| |
TREATMENT OF VENOUS THROMBOEMBOLISM:
DURATION AND NEW OPTIONS
M.V. Huisman (Leiden University Medical Centre, Leiden, The
Netherlands) |
EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room C (Geneva Palexpo)
| Chair: |
J. Apperley (Hammersmith Hospital, London, United
Kingdom) |
| |
OVERVIEW OF TRANSPLANT ACTIVITY
IN EUROPE
A. Gratwohl (Kantonsspital Basel, Basel, Switzerland) |
| |
REDUCED INTENSITY TRANSPLANT: WHERE ARE
WE NOW?
S. MacKinnon (University College London, London, United Kingdom)
|
| |
LONG-TERM CARE AFTER STEM CELL TRANSPLANTATION
G. Socié (Hospital Saint-Louis, Paris, France) |
|
Top
|
